logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure GPS-18. Overview of drug prevalence estimates in Europe for all adults (aged 15–64) and young adults (aged 15–34) [see all figures in this series...]

Part (i) Cannabis use — lifetime experience, last 12 months and last 30 days prevalence


Data are from the most recent national surveys available in each country (see General population survey tables, EMCDDA Statistical bulletin 2011).

For each country, the average of the sample prevalences, weighted by sample size, is indicated by the highlighted data point


Statistical bulletin 2006: Figure GPS-33 part (i)

Statistical bulletin 2007: Figure GPS-18 part (i)

Statistical bulletin 2008: Figure GPS-18 part (i)

Statistical bulletin 2009: Figure GPS-18 part (i)

Statistical bulletin 2010: Figure GPS-18 part (i)

See also Table GPS-0

For details of the studies included see Tables GPS-7 to GPS-9

See also 'General notes for interpreting data' on the Explanatory notes and help page


Reitox national reports 2010, taken from population surveys, reports or scientific articles.

(see the help page for information about formats etc.)

Page last updated: Tuesday, 02 August 2011